Psoriasis

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 8, 2014, Pages

  Di Meglio, Paola ^a   Villanova, Federica ^b,c   Nestle, Frank O ^b,c  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ABATACEPT; ADALIMUMAB; ALEFACEPT; AN 2728; APREMILAST; BARICITINIB; BRIAKINUMAB; BRODALUMAB; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; FEZAKINUMAB; GUSELKUMAB; IMIQUIMOD; INCB 01824; INFLIXIMAB; IXEKIZUMAB; METHOTREXATE; MK 3222; RETINOID; SECUKINUMAB; SOTRASTAURIN; TOFACITINIB; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VITAMIN D DERIVATIVE; BIOLOGICAL FACTOR; BIOLOGICAL MARKER; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY; PROTEIN; PSORS1C1 PROTEIN, HUMAN;

ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONDYLOMA ACUMINATUM; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENETIC RISK; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; NON MELANOMA SKIN CANCER; NONHUMAN; PATHOGENESIS; PHOTOTHERAPY; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; QUALITY OF LIFE; RISK FACTOR; CLASSIFICATION; ENVIRONMENT; FORECASTING; GENETIC PREDISPOSITION; GENETICS; IMMUNE SYSTEM; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; BIOLOGICAL MARKERS; DERMATOLOGIC AGENTS; ENVIRONMENT; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; PROTEINS; PSORIASIS;

EID: 84921554688     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a015354     Document Type: Article

References (256)

1. Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, Abildstrom SZ, Skov L, Torp-Pedersen C, Hansen PR. 2011. Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study. J Intern Med 270: 147-157.
2. Ainali C, Valeyev N, Perera G, Williams A, Gudjonsson JE, Ouzounis CA, Nestle FO, Tsoka S. 2012. Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics 13: 472.
3. Amgen. 2013a. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-2). Clinical-trials.gov/ct2/show/NCT01708603.
4. Amgen. 2013b. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-3). clinical-trials.gov/ct2/show/NCT01708629.
5. Amgen. 2013c. Study of efficacy, safety, and withdrawal and retreatment with brodalumab in moderate to severe plaque psoriasis subjects (AMAGINE-1). http://clinical-trials.gov/ct2/show/NCT01708590.
6. Anacor. 2013a. AN2728 Topical ointment to treat mild-to-moderate plaque-type psoriasis. clinicaltrials.gov/ct2/ show/NCT01300052?term=01300052&rank=1.
7. Anacor. 2013b. Safety and efficacy study of a novel ointment to treat plaque type psoriasis. clinicaltrials.gov/ct2/ show/NCT01029405?term=01029405&rank=1.
8. Anacor. 2013c. Safety and efficacy study of a novel ointment to treat plaque type psoriasis. clinicaltrials.gov/ct2/results?term=00759161.
9. Anancor. 2013d. Safety and efficacy study of a novel ointment to treat plaque type psoriasis. clinicaltrials.gov/ ct2/show/NCT00755196
10. Anandarajah AP, Ritchlin CT. 2009. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol 5: 634-641.
11. Arican O, Aral M, Sasmaz S, Ciragil P. 2005. Serum levels of TNF-a, IFN-g, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005: 273-279.
12. Armstrong AW, Harskamp CT, Armstrong EJ. 2013a. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol 68: 654-662.
13. Armstrong AW, Harskamp CT, Armstrong EJ. 2013b. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatol 149: 84-91.
14. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferong, interleukin-2, and tumor necrosis factor-a, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113: 752-759.
15. Ayala F. 2007. Clinical presentation of psoriasis. Reumatismo 59: 40-45.
16. Boy MG, Wang C, Wilkinson BE, Chow VF, Clucas AT, Krueger JG, Gaweco AS, Zwillich SH, Changelian PS, Chan G. 2009. Double-blind, placebocontrolled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 129: 2299-2302.
17. Boyd AS, Menter A. 1989. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 21: 985-991.
18. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-a. J Exp Med 199: 731-736.
19. Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. 2007. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol 28: 51-57.
20. Brandrup F, Hauge M, Henningsen K, Eriksen B. 1978. Psoriasis in an unselected series of twins. Arch Dermatol 114: 874-878.
21. Bristol-Myers Squibb. 2013. Phase II randomized, double-blind, placebo-controlled study of BMS-188667 (CTLA4Ig) in patients with psoriasis vulgaris. clinical-trials.gov/ct2/show/NCT00287547?term=00287547& rank=1.
22. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang HG, Wang T, Zheng J, et al. 2011. Pivotal role of dermal IL-17-producing gd T cells in skin inflammation. Immunity 35: 596-610.
23. Cai Y, Fleming C, Yan J. 2012. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 9: 302-309.
24. Can-Fite. 2013. Trial of CF101 to treat patients with psoriasis. clinicaltrials.gov/ct2/show/NCT01265667?term=Cf101%2C+psoriasis&rank=2.
25. Capon F, Bijlmakers MJ, Wolf N, Quaranta M, Huffmeier U, Allen M, Timms K, Abkevich V, Gutin A, Smith R, et al. 2008. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet 17: 1938-1945.
26. Capon F, Burden AD, Trembath RC, Barker JN. 2012. Psoriasis and other complex trait dermatoses: From Loci to functional pathways. J Invest Dermatol 132: 915-922.
27. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanes JJ, et al. 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273-290.
28. Celgene. 2013a. Phase 3b Safety and efficacy study of apremilast to treat moderate to severe plaque-plaque psoriasis. clinicaltrials.gov/ct2/show/NCT01690299.
29. Celgene. 2013b. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis (ESTEEM 1). clinicaltrials.gov/ ct2/show/NCT01194219.
30. Celgene. 2013c. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis. (ESTEEM 2). clinicaltrials.gov/ct2/show/NCT01232283.
31. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, et al. 2005. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci 102: 2075-2080.
32. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB, et al. 2006. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203: 2577-2587.
33. Chandran V, Raychaudhuri SP. 2010. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34: J314-J321.
34. Chang JC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, et al. 1994. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V b3 and/or V b13.1 genes. Proc Natl Acad Sci 91: 9282-9286.
35. Chen H, Poon A, Yeung C, Helms C, Pons J, Bowcock AM, Kwok PY, Liao W. 2011. A genetic risk score combining ten psoriasis risk loci improves disease prediction. PloS ONE 6: e19454.
36. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG. 2011. Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131: 677-687.
37. Clark RA. 2010. Skinresident T cells: The ups and downs of on site immunity. J Invest Dermatol 130: 362-370.
38. Clop A, Bertoni A, Spain SL, Simpson MA, Pullabhatla V, Tonda R, Hundhausen C, Di Meglio P, De Jong P, Hayday AC, et al. 2013. An in-depth characterization of the major psoriasis susceptibility locus identifies candidate susceptibility alleles within an HLA-C enhancer element. PloS ONE 8: e71690.
39. Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougerolles A, Kotelianski V, Gardner H, Nestle FO. 2007. a1b1 Integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 13: 836-842.
40. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, FitzGerald OM. 2001. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 166: 2878-2886.
41. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS. 2002. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells. J Immunol 168: 4462-4471.
42. David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, et al. 2012. Treatment of plaque-type psoriasis with oral CF101: Data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 26: 361-367.
43. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, Stahle M, Nestle FO, Girolomoni G, et al. 2010. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and comorbid conditions. J Invest Dermatol 130: 1785-1796.
44. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, van Maldegem F, Aten J, van der Wal AC. 2010. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 220: 499-508.
45. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, Giardina E, Stuart PE, Nair R, Helms C, et al. 2009. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 41: 211-215.
46. Dellavalle RP, Johnson KR. 2005. Do smoking, obesity, and stress cause psoriasis? J Invest Dermatol 125: 4-11
47. De Simone C, Caldarola G, Coco V, Palumbo S, Pocino K, Sgambato A, Maiorino A, Corbi M, Sandri MT, Vendittelli F, et al. 2013. Circulating endothelial cell levels in psoriatic patients and their modification after an anti-TNF-a (Etanercept) treatment. J Eur Acad Dermatol Venereol doi: 10.1111/jdv.12140.
48. Di Cesare A, Di Meglio P, Nestle FO. 2009. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-1350.
49. Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC. 2006. Identical TCR b-chain rearrangements in strep-tococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 176: 7104-7111.
50. Di Meglio P, Di Cesare A, Laggner U, Chu C-C, Napolitano L, Villanova F, Tosi I, Capon F, Trembath RC, Peris K, et al. 2011a. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans PLoS ONE 6: e17160.
51. Di Meglio P, Perera GK, Nestle FO. 2011b. The multitasking organ: Recent insights into skin immune function. Immunity 35: 857-869.
52. Di Meglio P, Villanova F, Napolitano L, Tosi I, Terranova Barberio M, Mak RK, Nutland S, Smith CH, Barker JN, Todd JA, et al. 2013. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol 133: 2381-2389.
53. Dowlatshahi EA, Kavousi M, Nijsten T, Ikram MA, Hofman A, Franco OH, Wakkee M. 2013. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: The Rotterdam Study. J Invest Dermatol 133: 2347-2354.
54. Duffy DL, Spelman LS, Martin NG. 1993. Psoriasis in Australian twins. J Am Acad Dermatol 29: 428-434.
55. Eder L, Chandran V, Pellett F, Pollock R, Shanmugarajah S, Rosen CF, Rahman P, Gladman DD. 2011. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis 70: 1594-1598.
56. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G. 2009. Interleukin-17 and interferong are produced concomitantly by human coronary arteryinfiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119: 1424-1432.
57. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Voorhees JJ, Abecasis GR, Nair RP. 2010. Molecular dissection of psoriasis: Integrating genetics and biology. J Invest Dermatol 130: 1213-1226.
58. Eli Lilly. 2013a. Evaluation of ixekizumab using autoinjector or prefilled syringe in participants with moderate to severe plaque psoriasis (UNCOVER-A). clinicaltrials. gov/ct2/show/NCT01777191.
59. Eli Lilly. 2013b. A phase 2b study of LY3009104 in participants with moderate to severe psoriasis. clinicaltrials. gov/ct2/show/NCT01490632?term=01490632& rank=1.
60. Eli Lilly. 2013c. A phase 3 study in participants with moderate to severe psoriasis (UNCOVER-2). clinicaltrials. gov/ct2/show/NCT01597245. Eli Lilly. 2013d. A study in Japanese participants with moderate-to-severe psoriasis. clinicaltrials.gov/ct2/show/ NCT01624233.
61. Eli Lilly. 2013e. A study in participants with moderate to severe psoriasis. clinicaltrials.gov/ct2/show/NCT01708590.
62. Eli Lilly. 2013f. A study in participants with moderate to severe psoriasis (UNCOVER-3). clinicaltrials.gov/ct2/ show/NCT01646177.
63. Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Belouchi M, Fournier H, Reinhard C, Ding J, et al. 2010. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 42: 991-995.
64. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, Debrus S, Raelson JV, Tejasvi T, Belouchi M, et al. 2012a. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 90: 636-647.
65. Ellinghaus E, Stuart PE, Ellinghaus D, Nair RP, Debrus S, Raelson JV, Belouchi M, Tejasvi T, Li Y, Tsoi LC, et al. 2012b. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol 132: 1133-1140.
66. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. 2006. An Italian study on psoriasis and depression. Dermatology 212: 123-127.
67. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, et al. 2009. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119: 3573-3585.
68. Farber EM, Nall ML, Watson W. 1974. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 109: 207-211.
69. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS. 2012. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367: 495-507.
70. Flutter B, Nestle FO. 2013. TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol 43: 3138-3146.
71. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. 2000. Flow cytometric characterization of lesional T cells in psoriasis: Intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 292: 519-521.
72. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M. 2009. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 206: 1983-1994.
73. Garbaraviciene J, Diehl S, Varwig D, Bylaite M, Ackermann H, Ludwig RJ, Boehncke WH. 2010. Platelet Pselectin reflects a state of cutaneous inflammation: Possible application to monitor treatment efficacy in psoriasis. Exp Dermatol 19: 736-741.
74. Garcia-Perez ME, Stevanovic T, Poubelle PE. 2013. New therapies under development for psoriasis treatment. Curr Opin Pediatr 25: 480-487.
75. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 10: 524-530.
76. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. 2006. Risk of myocardial infarction in patients with psoriasis. JAMA 296: 1735-1741.
77. Geremia A, Arancibia-Carcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP, Powrie F. 2011. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208: 1127-1133.
78. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, Nestle FO, Dummer R. 2004. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 140: 1490-1495.
79. Gisondi P, Malerba M, Malara G, Puglisi Guerra A, Sala R, Radaeli A, Calzavara-Pinton P, Girolomoni G. 2010. Creactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol 23: 1195-1202.
80. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. 2005. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64: 14-17.
81. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A. 2003. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 290: 3073-3080.
82. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, et al. 2006. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55: 598-606.
83. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51: 534-542.
84. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. 2005. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175: 2721-2729.
85. Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL. 2006. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial. J Am Acad Dermatol 54: S154-S163.
86. Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. 2011. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165: 652-660.
87. Griffiths CE, Barker JN. 2007. Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271.
88. Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne JP, Fry L. 2007. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 156: 258-262.
89. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, et al. 2010. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362: 118-128.
90. Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, Hauksson VB, Upmanyu R, Gulcher J, Stefansson K, Valdimarsson H. 2003. Psoriasis patients who are homozygous for the HLA-Cw 0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol 148: 233-235.
91. Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT. 2007. Mouse models of psoriasis. J Invest Dermatol 127: 1292-1308.
92. Gudjonsson JE, Johnston A, Ellis CN. 2012. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol 67: 139-147.
93. Gullick NJ, Evans HG, Church LD, Jayaraj DM, Filer A, Kirkham BW, Taams LS. 2010. Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PloS ONE 5: e12516.
94. Gunderson AJ, Mohammed J, Horvath FJ, Podolsky MA, Anderson CR, Glick AB. 2013. CD8+ T cells mediate RAS-induced psoriasis-like skin inflammation through IFN-g. J Invest Dermatol 133: 955-963.
95. Gupta MCS, Borkar M, Chandankhede M. 2011. Dyslipidemia and oxidative stress in patients of psoriasis. Biomed Res 22: 221-224.
96. Haider AS, Lowes MA, Gardner H, Bandaru R, Darabi K, Chamian F, Kikuchi T, Gilleaudeau P, Whalen MS, Cardinale I, et al. 2007. Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 178: 7442-7449.
97. Hammar H, Gu SQ, Johannesson A, Sundkvist KG, Biberfeld P. 1984. Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor/cytotoxic T cells in epidermis during the evolution of the lesion. J Invest Dermatol 83: 416-420.
98. Hart PH, Gorman S, Finlay-Jones JJ. 2011. Modulation of the immune system by UV radiation: More than just the effects of vitamin D? Nat Rev Immunol 11: 584-596.
99. Hebert HL, Ali FR, Bowes J, Griffiths CE, Barton A, Warren RB. 2012. Genetic susceptibility to psoriasis and psoriatic arthritis: Implications for therapy. Br J Dermatol 166: 474-482.
100. Henseler T, Christophers E. 1985. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13: 450-456.
101. Hijnen D, Knol EF, Gent YY, Giovannone B, Beijn SJ, Kupper TS, Bruijnzeel-Koomen CA, Clark RA. 2013. CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-g, IL-13, IL-17, and IL-22. J Invest Dermatol 133: 973-979.
102. Hsu LN, Armstrong AW. 2012. Psoriasis and autoimmune disorders: A review of the literature. J Am Acad Dermatol 67: 1076-1079.
103. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, Apel M, McManus R, Ho P, et al. 2010. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42: 996-999.
104. Hundhausen C, Bertoni A, Mak RK, Botti E, Di Meglio P, Clop A, Laggner U, Chimenti S, Hayday AC, Barker JN, et al. 2012. Allele-specific cytokine responses at the HLA-C locus: Implications for psoriasis. J Invest Dermatol 132: 635-641.
105. Hunt KA, Mistry V, Bockett NA, Ahmad T, Ban M, Barker JN, Barrett JC, Blackburn H, Brand O, Burren O, et al. 2013. Negligible impact of rare autoimmunelocus coding-region variants on missing heritability. Nature 498: 232-235.
106. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. 2009. Trends in incidence of adult-onset psoriasis over three decades: A population-based study. J Am Acad Dermatol 60: 394-401.
107. Incyte. 2013. A study of escalating doses of INCB039110 administered orally in patients with plaque psoriasis. clinicaltrials.gov/ct2/show/NCT01634087?term=01634 087&rank
108. Jabbari A, Suarez-Farinas M, Dewell S, Krueger JG. 2012. Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. J Invest Dermatol 132: 246-249.
109. Janssen. 2013. A study to evaluate CNTO 1959 in the treatment of patients with moderate to severe plaque-type psoriasis (X-PLORE). clinicaltrials.gov/ct2/show/ NCT01483599.
110. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. 2012. Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity. Nature 483: 227-231.
111. Jin Y, Yang S, Zhang F, Kong Y, Xiao F, Hou Y, Fan X, Zhang X. 2009. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: A hospital-based case-control study in China. J Eur Acad Dermatol Venereol 23: 132-137.
112. Johansen C, Vinter H, Soegaard-Madsen L, Olsen LR, Steiniche T, Iversen L, Kragballe K. 2010. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNF-a therapy. Br J Dermatol 163: 1194-1204.
113. Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, et al. 2013. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 190: 2252-2262.
114. Jokai H, Szakonyi J, Kontar O, Barna G, Inotai D, Karpati S, Hollo P. 2013. Cutaneous lymphocyteassociated antigen as a novel predictive marker of TNF-a inhibitor biological therapy in psoriasis. Exp Dermatol 22: 221-223.
115. Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, et al. 2012a. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kB, in psoriasis. Am J Hum Genet 90: 796-808.
116. Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, et al. 2012b. PSORS2 is due to mutations in CARD14. Am J Hum Genet 90: 784-795.
117. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P. 2004. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action. Dermatology 208: 297-306.
118. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. 2010. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130: 1373-1383.
119. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. 2008. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol 88: 337-340.
120. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. 2008. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 159: 1364-1367.
121. Kim GK, Del Rosso JQ. 2010. Drug-provoked psoriasis: Is it drug induced or drug aggravated? Understanding path-ophysiology and clinical relevance. J Clin Aesthet Dermatol 3: 32-38.
122. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. 2002. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47: 821-833.
123. Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, et al. 2012. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130: 145-154
124. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, et al. 2008. Induction of IL-17+ T cell trafficking and development by IFN-g: Mechanism and pathological relevance in psoriasis. J Immunol 181: 4733-4741.
125. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. 2010. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol 146: 891-895.
126. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N, Smith CH, Hayday AC, Nickoloff BJ, Nestle FO. 2011. Identification of a novel proinflammatory human skin-homing Vg9Vd2 T cell subset with a potential role in psoriasis. J Immunol 187: 2783-2793.
127. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Su B, Nestle FO, Zal T, et al. 2007. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564-569.
128. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. 2003a. An international, randomized, double-blind, placebo-controlled phase 3 trial of intra-muscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139: 719-727.
129. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, et al. 2003b. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004-2013.
130. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-130.
131. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. 2003. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349: 2014-2022.
132. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB. 2005. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 52: 425-433.
133. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. 2008a. Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 158: 1107-1116.
134. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. 2008b. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
135. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. 2012. Antiintereukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366: 1190-1199.
136. Li WQ, Han JL, Chan AT, Qureshi AA. 2013. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis 72: 1200-1205.
137. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. 2011. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187: 490-500.
138. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger CR, et al. 2008. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4: e1000041.
139. Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. 2012. Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis. Adv Ther 29: 620-634.
140. Lomholt G, ed. 1963. Psoriasis: Prevalence, spontaneous course, and genetics. GEC GAD, Copenhagen.
141. Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. 2013. Heritability of psoriasis in a large twin sample. Br J Dermatol 169: 412-416.
142. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128: 1207-1211.
143. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. 2013. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34: 174-181.
144. Lu Y, Chen H, Nikamo P, Qi Low H, Helms C, Seielstad M, Liu J, Bowcock AM, Stahle M, Liao W. 2013. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol 133: 836-839.
145. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118: 597-607.
146. Mak RK, Hundhausen C, Nestle FO. 2009. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 100: 2-13.
147. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, et al. 2009. Finding the missing heritability of complex diseases. Nature 461: 747-753.
148. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. 2005. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 52: 402-411.
149. Marongiu F, Sorano GG, Bibbo C, Pistis MP, Conti M, Mulas P, Balestrieri A, Biggio P. 1994. Abnormalities of blood coagulation and fibrinolysis in psoriasis. Dermatology 189: 32-37.
150. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, Zribi J, Bal E, Cluzeau C, Chrabieh M, et al. 2011. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365: 620-628.
151. Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gurtler L, Riethmuller G, Prinz JC. 1995. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 155: 4078-4083.
152. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W. 2005. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141: 31-38.
153. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. 2007. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56: 31.e1-e15.
154. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, et al. 2008. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 58: 106-115.
155. Merck. 2013a. A study to evaluate the efficacy and safety of subcutaneous MK-3222, followed by an optional long-term safety extension study, In participants with moderate-to-severe chronic plaque psoriasis (MK-3222-010 A M3). clinicaltrials.gov/ct2/show/NCT01722331.
156. Merck. 2013b. A study to evaluate the efficacy and safety/ tolerability of subcutaneous SCH 900222/MK-3222 in participants with moderate-to-severe chronic plaque psoriasis (P07771/MK-3222-011). clinicaltrials.gov/ ct2/show/NCT01729754.
157. Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, Westphal E, Guo SW, Christophers E, Voorhees JJ, et al. 1997. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 6: 1349-1356.
158. Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, Schork NJ, Kim J, Lim HW, Christophers E, et al. 2000. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66: 1833-1844.
159. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, Weichenthal M, Abecasis GR, Lim HW, Christophers E, et al. 2006. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78: 827-851.
160. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, et al. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kB pathways. Nat Genet 41: 199-204.
161. Najarian DJ, Gottlieb AB. 2003. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol 48: 805-821.
162. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, Bruni PL, Ingordo V, Lo Scocco G, Solaroli C, et al. 2005. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case-control study. J Invest Dermatol 125: 61-67.
163. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ, Gilliet M. 2005. Plasmacytoid predendritic cells initiate psoriasis through interferona production. J Exp Med 202: 135-143.
164. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. 2009. Skin immune sentinels in health and disease. Nat Rev Immunol 9: 679-691.
165. Nickoloff BJ. 1991. The cytokine network in psoriasis. Arch Dermatol 127: 871-884.
166. Novartis. 2013a. A dose finding study of AEB071 assessing psoriasis area and severity index in patients with plaque psoriasis. http://clinicaltrials.gov/ct2/show/ NCT01194219. Accessed July 26, 2013.
167. Novartis. 2013b. Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase iii studies with secukinumab. http://clinicaltrials.gov/ct2/show/NCT01544595?term=NCT01544595&rank=1. Accessed July 26, 2013.
168. O’Leary CJ, Creamer D, Higgins E, Weinman J. 2004. Perceived stress, stress attributions and psychological distress in psoriasis. J Psychosom Res 57: 465-471.
169. Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, Knight J, Spain SL, Nestle FO, Burden AD, et al. 2011. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 89: 432-437.
170. Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, Santamaria M. 2009. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 86: 435-443.
171. Ozden MG, Tekin NS, Gurer MA, Akdemir D, Dogramaci C, Utas S, Akman A, Evans SE, Bahadir S, Ozturkcan S, et al. 2011. Environmental risk factors in pediatric psoriasis: A multicenter case-control study. Pediatr Dermatol 28: 306-312.
172. Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, Becher B. 2012. Rorgt+ innate lymphocytes and gd T cells initiate psoriasiform plaque formation in mice. J Clin Invest 122: 2252-2256.
173. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 152: 1304-1312.
174. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A. 2006. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial. Int J Dermatol 45: 605-614.
175. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, et al. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
176. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. 2012a. Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet 380: 738-746.
177. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, et al. 2012b. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366: 1181-1189.
178. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. 2012c. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 167: 668-677.
179. Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J. 2012d. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 66: e33-e45.
180. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, et al. 2013a. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up. Br J Dermatol 168: 844-854.
181. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. 2013b. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168: 412-421.
182. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. 2013. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 133: 377-385.
183. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, et al. 2012. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 223: 1-68.
184. Perera GK, Di Meglio P, Nestle FO. 2012. Psoriasis. Annu Rev Pathol 7: 385-422.
185. Pfizer. 2013. Study evaluating the safety and tolerability of ILV-094 in subjects with psoriasis. http://clinicaltrials.gov/ct2/show/NCT00563524. Accessed July 26, 2013.
186. Picardi A, Lega I, Tarolla E. 2013. Suicide risk in skin disorders. Clin Dermatol 31: 47-56.
187. Piruzian E, Bruskin S, Ishkin A, Abdeev R, Moshkovskii S, Melnik S, Nikolsky Y, Nikolskaya T. 2010. Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC Syst Biol 4: 41.
188. Pitzalis C, Cauli A, Pipitone N, Smith C, Barker J, Marchesoni A, Yanni G, Panayi GS. 1996. Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum 39: 137-145.
189. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K. 2013. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169: 137-145.
190. Poulin Y, Langley RG, Teixeira HD, Martel MJ, Cheung S. 2009. Biologics in the treatment of psoriasis: Clinical and economic overview. J Cutan Med Surg 13: S49-S57.
191. Prinz JC. 2001. Psoriasis vulgaris—A sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 26: 326-332.
192. Prinz JC, Vollmer S, Boehncke WH, Menssen A, Laisney I, Trommler P. 1999. Selection of conserved TCR VDJ rear-rangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol 29: 3360-3368.
193. Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A. 2012. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 67: 658-664.
194. Ramirez-Carrozzi V, Sambandam A, Luis E, Lin Z, Jeet S, Lesch J, Hackney J, Kim J, Zhou M, Lai J, et al. 2011. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 12: 1159-1166.
195. Rashmi R, Rao KS, Basavaraj KH. 2009. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 34: 658-663.
196. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. 2005. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 366: 1367-1374.
197. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, et al. 2013. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168: 402-411.
198. Roberson ED, Liu Y, Ryan C, Joyce CE, Duan S, Cao L, Martin A, Liao W, Menter A, Bowcock AM. 2012. A sub-set of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol 132: 583-592.
199. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. 2004. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 150: 917-928.
200. Russell TJ, Schultes LM, Kuban DJ. 1972. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med 287: 738-740.
201. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. 2013. Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis. J Invest Dermatol 133: 2340-2346.
202. Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, Green J, Griffiths CE, Holgate S, Jones D, et al. 2013. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov 12: 306-324.
203. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A. 2008. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158: 558-566.
204. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Buschenfelde KH, Fleischer B. 1994. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102: 145-149.
205. Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, Allen MA, Burden AD, Griffiths CE, Seyger MM, et al. 2013. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol 133: 1366-1369.
206. Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. 2006. Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 12: 22-28.
207. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. 2009. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 55: 62-63.
208. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, Maverakis E. 2013. Biologic therapies in the treatment of psoriasis: A comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 44: 121-140.
209. Sjogren F, Davidsson K, Sjostrom M, Anderson CD. 2012. Cutaneous microdialysis: Cytokine evidence for altered innate reactivity in the skin of psoriasis patients? AAPS J 14: 187-195.
210. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. 2011. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305: 2525-2531.
211. Spits H, Cupedo T. 2012. Innate lymphoid cells: Emerging insights in development, lineage relationships, and function. Annu Rev Immunol 30: 647-675.
212. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, et al. 2013. Innate lymphoid cells—A proposal for uniform nomenclature. Nat Rev Immunol 13: 145-149.
213. Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C, Bergboer JG, et al. 2010. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42: 985-990.
214. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. 2011. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165: 661-668.
215. Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE, Li Y, Weidinger S, Eberlein B, Gieger C, et al. 2010. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42: 1000-1004.
216. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG. 2011. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 131: 391-400.
217. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. 2012. Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 132: 2552-2564.
218. Sun LD, Cheng H, Wang ZX, Zhang AP, Wang PG, Xu JH, Zhu QX, Zhou HS, Ellinghaus E, Zhang FR, et al. 2010. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 42: 1005-1009.
219. Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, Xing X, Nair RP, Voorhees JJ, Elder JT, et al. 2011. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS ONE 6: e18266.
220. Tan CS, Koralnik IJ. 2010. Progressive multifocal leukoen-cephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol 9: 425-437.
221. Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P, Elder JT, Nair RP. 2012. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 132: 593-600.
222. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, Suarez-Farinas M. 2012. Meta-analysis derived (MAD) transcriptome of psoriasis defines the “core” pathogenesis of disease. PLoS ONE 7: e44274.
223. Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. 1980. Psoriasis and HLA-Cw6. Br J Dermatol 102: 179-184.
224. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. 2010. Incidence of psoriasis in children: A population-based study. J Am Acad Dermatol 62: 979-987.
225. Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, Blumenschein WM, Qin JZ, Xin H, Oldham E, et al. 2010. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol 185: 5688-5691.
226. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop GM, et al. 1997. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6: 813-820.
227. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, et al. 2012. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44: 1341-1348.
228. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, et al. 2006. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 367: 29-35.
229. Updike J. 1976. From the journal of a leper. The New Yorker July19: 28-33.
230. Updike J. 1985. Personal history: At war with my skin. The New Yorker September 2: 39-57.
231. Updike J. 1989. Self-consciousness: Memoirs. Penguin, London.
232. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, Gudjonsson JE, Johnston A. 2009. Psoriasis—As an autoimmune disease caused by molecular mimicry. Trends Immunol 30: 494-501.
233. Valeyev NV, Hundhausen C, Umezawa Y, Kotov NV, Williams G, Clop A, Ainali C, Ouzounis C, Tsoka S, Nestle FO. 2010. A systems model for immune cell interactions unravels the mechanism of inflammation in human skin. PLoS Comput Biol 6: e1001024.
234. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, et al. 2009. Imiquimodinduced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182: 5836-5845.
235. van de Kerkhof PCM, Nestle FO. 2012. Psoriasis. In Dermatology (ed. Bolognia JL, Jorizzo JL, Schaffer JV). Elsevier, Amsterdam.
236. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, et al. 2012. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367: 508-519.
237. Veal CD, Capon F, Allen MH, Heath EK, Evans JC, Jones A, Patel S, Burden D, Tillman D, Barker JN, et al. 2002. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 71: 554-564.
238. Villanova F, Di Meglio P, Nestle FO. 2013a. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis 72: 104-110.
239. Villanova F, Flutter B, Tosi I, Grys K, Sreeneebus H, Perera GK, Chapman A, Smith CH, Di Meglio P, Nestle FO. 2013b. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol 134: 984-991.
240. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. 2013. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis 72: 165-178.
241. Vollmer S, Menssen A, Prinz JC. 2001. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: Evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 117: 1296-1301.
242. Wang F, Lee E, Lowes MA, Haider AS, Fuentes-Duculan J, Abello MV, Chamian F, Cardinale I, Krueger JG. 2006. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 126: 1590-1599.
243. Watt FM. 1989. Terminal differentiation of epidermal keratinocytes. Curr Opin Cell Biol 1: 1107-1115.
244. Weiss G, Shemer A, Trau H. 2002. The Koebner phenomenon: Review of the literature. J Eur Acad Dermatol Venereol 16: 241-248.
245. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8: 950-957.
246. Wolfe F, Freundlich B, Straus WL. 2003. Increase in cardio-vascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30: 36-40.
247. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, Worthington J, Griffiths CE, Mathew CG, Barker JN, et al. 2008. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 45: 114-116.
248. Wolf R, Mascia F, Dharamsi A, Howard OM, Cataisson C, Bliskovski V, Winston J, Feigenbaum L, Lichti U, Ruzicka T, et al. 2010. Gene from a psoriasis susceptibility locus primes the skin for inflammation. Sci Transl Med 2: 61-90.
249. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, White B, Coyle A, Krueger J, Kiener PA, et al. 2008. Type I interferon: Potential therapeutic target for psoriasis? PloS ONE 3: e2737.
250. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. 2011. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 106: 741-747.
251. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, Novitskaya I, Khatcherian A, Bluth MJ, Lowes MA, et al. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204: 3183-3194.
252. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, Lowes MA. 2009a. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129: 79-88.
253. Zaba LC, Krueger JG, Lowes MA. 2009b. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol 129: 302-308.
254. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG. 2009c. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124: 1022-10.
255. Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, Zhang FR, Zhang C, Du WH, Pu XM, et al. 2009. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41: 205-210.
256. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. 2007. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.